PARP1 and metabolic dysfunction-associated steatotic liver disease: In the livers of patients with NAFLD, increased poly (ADP-ribose) polymerase 1 (PARP1) activity represses PPARα transactivation and may lead to weakened fatty acid oxidation [157].